Observation and Nursing for Adverse Reactions of PD-1 Inhibitor Combined With Locoregional Therapy for the Treatment of Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus

Objective To summarize nursing care for adverse reactions of programmed death 1（PD-1） inhibitor combined with locoregional therapy for the treatment of hepatocellular carcinoma patients with portal vein tumor thrombus（PVTT）. Methods A total of 68 hepatocellular carcinoma patients with PVTT undergoing PD-1 inhibitor combined with locoregional therapy were enrolled. The adverse reactions were observed and nursing care was provided. Results Liver pain occurred in 20 patients, fever in 8 patients, fatigue and alimentary tract symptoms such as anorexia in 45 patients, liver function damage in 26 patients, interstitial pneumonia in 1 patients, nerve toxicity in 1 patients, all patients were discharged after recovery. Conclusions Liver pain, fever, fatigue and alimentary tract symptoms such as anorexia, liver function damage were common adverse reactions after PD-1 inhibitor combined with locoregional therapy, effective measures should be taken to reduce the occurrence of adverse reactions.